April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
14 citations
,
April 2017 in “American Journal of Transplantation” Skin problems from transplant drugs are common and need careful management in organ transplant patients.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
A reliable method was developed to measure gemcitabine and olaparib in pancreatic tissue, aiding pancreatic cancer treatment.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
6 citations
,
June 1983 in “Cancer” A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
1 citations
,
January 2025 in “RSC Advances” Ascorbic acid derivatives improve drug delivery systems.
November 2022 in “Journal of the Endocrine Society” Long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
2 citations
,
March 2024 in “Supportive Care in Cancer” Penguin Cold Caps help most patients keep at least half their hair during chemotherapy.
October 2022 in “Hair Transplantation” Be ready for emergencies during hair restoration surgery.
April 2025 in “Suez Canal University Medical Journal” Valproic acid can rarely cause fluid buildup around the lungs and heart.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
The treatment was not recommended due to limited effectiveness and significant side effects.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
January 2008 in “프로그램북(구 초록집)”
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
July 2025 in “Reactions Weekly”
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
3 citations
,
November 2023 in “Journal of Investigative Dermatology” Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
75 citations
,
June 2005 in “Archives of Dermatology” Etanercept may not prevent alopecia areata from coming back.
The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.
July 2020 in “CRS 2020 Virtual Annual Meeting” Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.
January 2017 in “Seoul National University Open Repository (Seoul National University)” AIMP1 can boost hair growth by increasing stem cell activity.
June 2024 in “Journal of Ayub Medical College Abbottabad” Combining PRP with Procapil is more effective for hair loss treatment than PRP alone.